AstraZeneca Results Presentation Deck

Appendix: Rare Diseases - a new growth area for AstraZeneca Recent and upcoming pipeline developments 39 Ultomiris gMG¹ (2nd-generation, long-acting C5 inhibitor) • Positive Phase III read-out July 2021; full data to be presented at future medical conference 1. Generalised myasthenia gravis. Regulatory submission to follow in H2 2021 and H1 2022 dadda Idda ddd dddd ddddd વવવા da Q2W IV Addressable gMG market SOLIRIS' (eculizumab) 100/20 Q8W IV ULTOMIRIS [ravulizumab cwvz] w Compelling product profile and value proposition will help expand addressable gMG population dd da lada Future Assets ALXN1840 Wilson Disease Phase III read-out anticipated H2 2021 Novel potential new treatment with convenient once-daily oral dosing Powered for superiority over standard-of-care chelators Potential for rapid and sustained control of copper and clinical symptoms Opportunity to revolutionise treatment in Wilson Disease B

View entire presentation